论文部分内容阅读
云桥生物技术公司最近开发的蛋白质构象矩阵ELISA技术(PCA-ELISA)能从分子水平上系统、灵敏并且快速的分析蛋白质药物的三维构象。最近美国的《医疗保健法》需确认为仿制药的审批和商业化指明了道路,届时将引起目前已上市的主要的生物药间的激烈竞争。如何保持生物仿制药与原创药的高度相似是目前生物制药产业所面临的巨大挑战,而争论的焦点集中在仿制药与原创
The recently developed Protein Conformation Matrix ELISA (PCA-ELISA) developed by Yunqiao Biotechnology Company enables systematic, sensitive and rapid analysis of the three-dimensional conformation of protein drugs at the molecular level. The recent U.S. law on health care needs to be identified as indicating the path to generic drug approval and commercialization, which will result in fierce competition between the major biopharmaceuticals currently on the market. How to keep a high degree of similarities between biosimilars and original drugs is a tremendous challenge for the biopharmaceutical industry at present, and the debate is focused on generic drugs and original